153 related articles for article (PubMed ID: 8782465)
1. DNA immunization induces protective immunity against B-cell lymphoma.
Syrengelas AD; Chen TT; Levy R
Nat Med; 1996 Sep; 2(9):1038-41. PubMed ID: 8782465
[TBL] [Abstract][Full Text] [Related]
2. A genetic approach to idiotypic vaccination for B cell lymphoma.
Stevenson FK; Zhu D; King CA; Ashworth LJ; Kumar S; Thompsett A; Hawkins RE
Ann N Y Acad Sci; 1995 Nov; 772():212-26. PubMed ID: 8546396
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection.
Syrengelas AD; Levy R
J Immunol; 1999 Apr; 162(8):4790-5. PubMed ID: 10202021
[TBL] [Abstract][Full Text] [Related]
4. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma.
Tao MH; Levy R
Nature; 1993 Apr; 362(6422):755-8. PubMed ID: 8469286
[TBL] [Abstract][Full Text] [Related]
5. A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines.
Hakim I; Levy S; Levy R
J Immunol; 1996 Dec; 157(12):5503-11. PubMed ID: 8955200
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
Kwak LW; Young HA; Pennington RW; Weeks SD
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293
[TBL] [Abstract][Full Text] [Related]
8. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
9. Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines.
Kanter G; Yang J; Voloshin A; Levy S; Swartz JR; Levy R
Blood; 2007 Apr; 109(8):3393-9. PubMed ID: 17164345
[TBL] [Abstract][Full Text] [Related]
10. Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype.
Selmayr M; Strehl J; Kremer JP; Kremmer E; Doenecke A; Hallek M; Menzel H; Thielemans K; Thierfelder S; Mocikat R
Gene Ther; 1999 May; 6(5):778-84. PubMed ID: 10505101
[TBL] [Abstract][Full Text] [Related]
11. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor.
Liu HM; Newbrough SE; Bhatia SK; Dahle CE; Krieg AM; Weiner GJ
Blood; 1998 Nov; 92(10):3730-6. PubMed ID: 9808567
[TBL] [Abstract][Full Text] [Related]
12. The development of a bicistronic plasmid DNA vaccine for B-cell lymphoma.
Singh G; Parker S; Hobart P
Vaccine; 2002 Jan; 20(9-10):1400-11. PubMed ID: 11818159
[TBL] [Abstract][Full Text] [Related]
13. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
Timmerman JM; Levy R
J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
[TBL] [Abstract][Full Text] [Related]
14. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor.
Chen TT; Tao MH; Levy R
J Immunol; 1994 Nov; 153(10):4775-87. PubMed ID: 7525715
[TBL] [Abstract][Full Text] [Related]
15. Construction and characterization of a chimeric fusion protein consisting of an anti-idiotype antibody mimicking a breast cancer-associated antigen and the cytokine GM-CSF.
Tripathi PK; Qin H; Bhattacharya-Chatterjee M; Ceriani RL; Foon KA; Chatterjee SK
Hybridoma; 1999 Apr; 18(2):193-202. PubMed ID: 10380019
[TBL] [Abstract][Full Text] [Related]
16. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells.
Fredriksen AB; Sandlie I; Bogen B
Mol Ther; 2006 Apr; 13(4):776-85. PubMed ID: 16414309
[TBL] [Abstract][Full Text] [Related]
17. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
18. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.
Levitsky HI; Montgomery J; Ahmadzadeh M; Staveley-O'Carroll K; Guarnieri F; Longo DL; Kwak LW
J Immunol; 1996 May; 156(10):3858-65. PubMed ID: 8621924
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
KoƧ ON; Redfern C; Wiernik PH; Rosenfelt F; Winter JN; Carter WD; Gold DP; Stewart ME; Ghalie RG; Bender JF
J Immunother; 2010; 33(2):178-84. PubMed ID: 20145546
[TBL] [Abstract][Full Text] [Related]
20. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.
Kwak LW; Campbell MJ; Czerwinski DK; Hart S; Miller RA; Levy R
N Engl J Med; 1992 Oct; 327(17):1209-15. PubMed ID: 1406793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]